Douglas Miehm
Stock Analyst at RBC Capital
(2.34)
# 1,191
Out of 4,653 analysts
41
Total ratings
53.57%
Success rate
-2.61%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $130 → $140 | $122.65 | +14.15% | 4 | Nov 12, 2024 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $10 → $11 | $8.87 | +24.08% | 18 | Nov 1, 2024 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $20 → $23 | $19.84 | +15.96% | 10 | Oct 22, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.22 | -2.68% | 9 | Feb 16, 2024 |
Ligand Pharmaceuticals
Nov 12, 2024
Maintains: Outperform
Price Target: $130 → $140
Current: $122.65
Upside: +14.15%
Bausch Health Companies
Nov 1, 2024
Maintains: Sector Perform
Price Target: $10 → $11
Current: $8.87
Upside: +24.08%
Bausch + Lomb
Oct 22, 2024
Maintains: Outperform
Price Target: $20 → $23
Current: $19.84
Upside: +15.96%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.22
Upside: -2.68%